Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

RecruitingOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

December 4, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2027

Conditions

DLBCL - Diffuse Large B Cell Lymphoma

Trial Locations (1)

RECRUITING

Incyte Biosciences Italy S.r.l, Milan

All Listed Sponsors

collaborator

Advice Pharma Group srl

INDUSTRY

lead

Incyte Biosciences Italy S.r.l

INDUSTRY